Fig. 2: Kaplan–Meier estimates of event-free survival from leukapheresis, progression-free survival from axi-cel infusion, overall survival from axi-cel infusion and duration of response. | Nature Medicine

Fig. 2: Kaplan–Meier estimates of event-free survival from leukapheresis, progression-free survival from axi-cel infusion, overall survival from axi-cel infusion and duration of response.

From: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial

Fig. 2

a–d, Kaplan–Meier estimates of EFS from leukapheresis (a), PFS from axi-cel infusion (b), OS from axi-cel infusion (c) and DOR (d). The blue-shaded areas around the survival curve represent the Hall–Wellner 95% confidence bands. NA, not attained.

Back to article page